Thomas Kassberg
President bei DIMENSION THERAPEUTICS INC
Vermögen: 12 Mio $ am 31.03.2024
Profil
Thomas Richard Kassberg was the founder of Plexxikon, Inc. (founded in 2000) where he held the title of Vice President-Business & Corporate Development from 2000 to 2004.
He is currently the Chief Business Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc. (since 2011) and the President at Dimension Therapeutics, Inc. (since 2017).
Mr. Kassberg's former positions include Senior Director-Corporate Licensing at Pharmacia, Inc., Principal at Bristol Myers Squibb Co., SVP-Business Development & Corporate Licensing at Sugen, Inc. (from 1995 to 1999), SVP-Corporate Development & Commercial Operations at InterMune, Inc. (from 2004 to 2007), Chief Business Officer at Melinta Subsidiary Corp., Executive Vice President-Corporate Development at Proteolix, Inc. (from 2008 to 2009), and Vice President-Business Development at Corium International, Inc. (from 2010 to 2011).
Mr. Kassberg obtained an MBA from Northwestern University in 1988 and an undergraduate degree from Gustavus Adolphus College in 1982.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 11.03.2024 | 252 823 ( 0,31% ) | 12 Mio $ | 31.03.2024 |
Aktive Positionen von Thomas Kassberg
| Unternehmen | Position | Beginn |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 21.11.2011 |
| DIMENSION THERAPEUTICS INC | President | 07.11.2017 |
Ehemalige bekannte Positionen von Thomas Kassberg
| Unternehmen | Position | Ende |
|---|---|---|
| CORIUM INTERNATIONAL INC | Corporate Officer/Principal | 01.10.2011 |
Proteolix, Inc.
 Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Corporate Officer/Principal | 01.09.2009 |
| INTERMUNE INC | Chief Operating Officer | 03.07.2007 |
Plexxikon, Inc.
 Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA. | Founder | 01.07.2004 |
Sugen, Inc.
 Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Corporate Officer/Principal | 01.01.1999 |
Ausbildung von Thomas Kassberg
| Northwestern University | Masters Business Admin |
| Gustavus Adolphus College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Sugen, Inc.
Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Plexxikon, Inc.
Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA. | Commercial Services |
Melinta Subsidiary Corp.
 Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Melinta Subsidiary Corp. develops and markets pharmaceutical products for the treatment of life-threatening infections. It also develops novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens. The company was founded by John N. Abelson, Harry F. Noller, Susan Froshauer, Harry H. Penner, Jr., William L. Jorgensen, Thomas A. Steitz, and Peter Moore in October 2000 and is headquartered in New Haven, CT. | Health Technology |
Proteolix, Inc.
Proteolix, Inc. Pharmaceuticals: MajorHealth Technology Proteolix, Inc. manufactures bio-pharmaceutical related products. It engages in the discovery, development, and marketing of pharmaceutical products to treat cancer and immunological conditions. The company was founded by Susan M. Molineauxf in December 2003 and is headquartered in South San Francisco, CA | Health Technology |
Corium International, Inc.
 Corium International, Inc. Pharmaceuticals: MajorHealth Technology Corium International, Inc. is a pharmaceutical company. It offers products such as corplex donepezil and memantine. The company was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1999 and is headquartered in Menlo Park, CA. | Health Technology |
| Pharmacia, Inc. | |
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
